Investigational drug · Phase 3
Pacibekitug
Also called: TOUR006, PAC001
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Myocardial Infarction, Thyroid Eye Disease, Chronic Kidney Diseases.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
2 still active
All registered trials
2
Any phase or sponsor naming "Pacibekitug"
First trial start
2024
Feb 19, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Pacibekitug", any sponsor or status.
Conditions studied
As listed on its trial records.
- Myocardial Infarction
- Thyroid Eye Disease
- Chronic Kidney Diseases
- Chronic Kidney Insufficiency
- Chronic Renal Diseases
- Chronic Renal Insufficiency
- Kidney Insufficiency, Chronic
- C-Reactive Protein
- High Sensitivity C-Reactive Protein
- Hs-CRP
Approved drugs for the same conditions: Coronary artery disease and heart attack · Chronic kidney disease · Cardiovascular and metabolic · Kidney and urology · Endocrinology and women's health
Largest trials
Live from ClinicalTrials.gov: studies naming "Pacibekitug" as an intervention, largest first.
- A Study to Assess the Effect of Pacibekitug on Major Cardiovascular Events in Patients After a Myocardial InfarctionPivotal-lookingNot yet recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07938411 · 10,000 participants (planned) · Start Nov 30, 2026 · Primary completion Oct 22, 2030
Drug: Pacibekitug; Placebo · For: Myocardial Infarction
- A Study to Evaluate TOUR006 in Patients With Chronic Kidney Disease and Elevated Hs-CRPPivotal-lookingCompleted
Tourmaline Bio, Inc., a Novartis CompanyIndustry
NCT06362759 · 143 participants · Start May 15, 2024 · Primary completion Mar 6, 2025
Drug: TOUR006 - 50 MG; TOUR006 - 25 MG and 1 more · For: Chronic Kidney Diseases; Chronic Kidney Insufficiency; Chronic Renal Diseases and 6 more
Sites: Birmingham, Alabama; Huntsville, Alabama; Phoenix, Arizona · 38 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Highlights of Cardiovascular Disease Prevention Studies Presented at the 2026 European Society of Cardiology Conference.
Abdul Jabbar AB, Zulfiqar K, Malik SAR, et al. · Curr Atheroscler Rep 2026
Also in development for Myocardial Infarction
- ZiltivekimabPhase 34 trials
Novo Nordisk · Acute Myocardial Infarction (AMI), Myocardial Infarction, Heart Failure
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.